At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHAT Phathom Pharmaceuticals
Pre-Mkt 07-20 07:49:36 EDT
10.94
-0.03
-0.27%
盘前10.89
-0.05-0.46%
05:42 EDT
High11.33Low10.86Vol480.19K
Open10.86D1 Closing10.97Amplitude4.28%
Mkt Cap868.97MTradable Cap686.83MTotal Shares79.43M
T/O5.31MT/O Rate0.76%Tradable Shares62.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)
TIPRANKS  ·  06-25
Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)
Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial
TIPRANKS  ·  06-23
Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial
Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna
MT Newswires Live  ·  06-23
Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna
Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults
Reuters  ·  06-23
Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 Phalcon-Eoe-201 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)
THOMSON REUTERS  ·  06-23
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 Phalcon-Eoe-201 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)
Phathom Pharmaceuticals - Topline Results From Phase 2 Trial Expected in Q4 2026
THOMSON REUTERS  ·  06-23
Phathom Pharmaceuticals - Topline Results From Phase 2 Trial Expected in Q4 2026
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
GlobeNewswire  ·  06-23
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  06-17
Wall Street Analysts Are Bullish on Top Healthcare Picks
Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Dow Jones  ·  06-17
Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Needham pharmaceuticals analysts hold analyst/industry conference call
TIPRANKS  ·  05-27
Needham pharmaceuticals analysts hold analyst/industry conference call
Phathom Pharma to present at Jefferies Global Healthcare Conference
Reuters  ·  05-22
Phathom Pharma to present at Jefferies Global Healthcare Conference
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  05-22
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals shareholders elected Class I directors at annual meeting
Reuters  ·  05-22
Phathom Pharmaceuticals shareholders elected Class I directors at annual meeting
Phathom presents Phase 3 pHalcon-NERD-301 vonoprazan symptom analysis at DDW 2026
Reuters  ·  05-20
Phathom presents Phase 3 pHalcon-NERD-301 vonoprazan symptom analysis at DDW 2026
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
GlobeNewswire  ·  05-20
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
Phathom (PHAT) Is Up 9.4% After Reaffirming 2026 Profitability Timeline And Narrowing Q1 Loss
Simply Wall St.  ·  05-09
Phathom (PHAT) Is Up 9.4% After Reaffirming 2026 Profitability Timeline And Narrowing Q1 Loss
Phathom to highlight VOQUEZNA at DDW annual meeting
Reuters  ·  05-01
Phathom to highlight VOQUEZNA at DDW annual meeting
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)
TIPRANKS  ·  05-01
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call
TIPRANKS  ·  05-01
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call
Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate
Benzinga  ·  04-30
Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate

Introduction

Company Name.
Phathom Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Issue price:
--